Objective: It was our aim to assess the usefulness of cytohistology in cervical thin layer brush samples with problems in the differential diagnosis of endometrial cells. Study Design: This study reveals the cytological, cytohistological and immunohistochemistry findings of 8 cases suspicious of adenocarcinoma in situ (AIS)/adenocarcinoma (AC) in cervical liquid-based cytology (LBC) preparations that turned out to be normal endometrial cells. Results: All 8 cervical LBCs featured endometrial and atypical endocervical-like columnar cells with frequent ragged ‘feathered’ edge appearance and rosette formations. Overlapping atypical glandular cell groups were present on 2 ThinPrep slides as well. In cytohistology of 7 cases, the recognition of endometrial stroma with endometrial glands easily allowed the diagnosis of normal endometrium. In 1 case with very small loose tissue fragments without glands, the diagnosis could be established by positivity for CD10 marker (endometrial stroma) and without proliferative activity in the Ki-67 immunostaining. Conclusion: In cervical LBC preparations, nuclear hyperchromasia, pleomorphism and nucleoli in normal endometrial cells are more obvious than in conventional smears, and their arrangement is sometimes suggestive of AIS or AC. In the 8 cases presented, we could avoid a false-positive diagnosis of AIS or AC through cytohistology/immunohistochemistry, and in consequence, unnecessary colposcopical/histological examination.

Keywords:
Liquid-based cervical cytology, Cytohistology, Immunohistochemistry, Normal endometrium
1.
Solomon D, Nayar R: The Bethesda System for Reporting Cervical Cytology, ed 2. New York, Springer Science and Business Media, 2004, p 58.
2.
Risse EKJ, Ouwerkerk-Noordam E, Meijer-Marres EM, Boon ME: Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies. Acta Cytol 2010;54:175–182.
3.
Boon ME, Ouwerkerk-Noordam E, Suurmeijer AJH, Kok LP: Diagnostic parameters in liquid-based cervical cytology using a coagulant suspension fixative. Acta Cytol 2005;49:513–519.
4.
Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki-67, p53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol 2007;26:71–75.
5.
Brown DC, Cole D, Gatter KC, Mason DY: Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki-67. Br J Cancer 1988;57:178–181.
6.
Garzetti GG, Ciavattini A, De Nictolis M, Lucarini G, Goteri G, Romanini C, Biagini G: MIB 1 immunostaining in cervical intraepithelial neoplasia: prognostic significance in mild and moderate lesions. Gynecol Obstet Invest 1996;42:261–266.
7.
Lambert AP, Anschau F, Schmitt VM: p16INK4a expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006;80:192–196.
8.
O’Neill CJ, McCluggage WG: p16INK4a expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8–15.
9.
Wentzensen N, Hampl M, Herkert M, Reichert A, Trunk MJ, Poremba C, Ridder R, von Knebel Doeberitz M: Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer 2006;107:2307–2313.
10.
Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S: p16INK4a overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 2006;448:597–603.
11.
Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T: Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004;102:100–108.
12.
Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ: The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535–543.
13.
Barroeta JE, Pasha TL, Acs G, Zhang PJ: Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. Int J Gynecol Pathol 2007;26:76–82.
14.
McCluggage WG, Sumathi VP, Maxwell P: CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273–278.
15.
Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S: Immunohistochemical analysis of the expression of CDK4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250–2256.
16.
Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN: Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 1999;79:1137–1143.
17.
de Peralta-Venturino MN, Purslow MJ, Kini SR: Endometrial cells of the ‘lower uterine segment’ (LUS) in cervical smears obtained by endocervical brushings: a source of potential diagnostic pitfall. Diagn Cytopathol 1995;12:263–271.
18.
Wilbur DC: Endocervical glandular atypia: a ‘new’ problem for the cytologist. Diagn Cytopathol 1995;13:463–469.
19.
Heaton RB Jr, Harris TF, Larson DM, Henry MR: Glandular cells derived from direct sampling of the lower uterine segment in patients status post-cervical cone biopsy. A diagnostic dilemma. Am J Clin Pathol 1996;106:511–516.
20.
Demay RM: Hyperchromatic crowded groups: pitfalls in Pap smear diagnosis. Am J Clin Pathol 2000;114(suppl):S36–S43.
21.
Lee KR, Genest DR, Minter LJ, Granter SR, Cibas ES: Adenocarcinoma in situ in cervical smears with a small cell (endometrioid) pattern: distinction from cells directly sampled from the upper endocervical canal or lower segment of the endometrium. Am J Clin Pathol 1998;109:738–742.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.